Walgreens Boots Alliance Stock - Weekly review and sector comparison after guidance cut
19.06.2026 - 14:47:14 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 14:41 CET. Details in the imprint.
Walgreens Boots Alliance (US9314271019) remains in focus for US retail investors after last week’s steep guidance cut and dividend suspension, which triggered a sharp sell-off in the shares, according to a Reuters overview of the stock’s recent moves. Against this backdrop, Friday trading is shaped by a broader look at the company’s week-on-week share performance and its positioning versus US pharmacy peers.
All news and data on Walgreens Boots Alliance stock
Key figures, background and further headlines on Walgreens Boots Alliance stock can be found in the dedicated topic overview on ad-hoc-news.de and on the company’s Investor Relations site.
What moved the stock recently
Walgreens Boots Alliance shocked parts of the market at the end of June when it sharply cut full-year adjusted earnings guidance and suspended its quarterly dividend to preserve cash, according to an IR release on third-quarter 2024 results. Management cited weaker retail demand in US pharmacies and continued reimbursement pressure in the core prescription business.
The earnings update reduced adjusted earnings-per-share guidance for fiscal 2024 to a corridor significantly below previous indications, while also signaling cost-cutting measures and store rationalizations. The surprise dividend suspension marked a clear break with the group’s historical payout profile and underscored the focus on strengthening the balance sheet.
Friday review and peer comparison
On a five-trading-day view, Walgreens Boots Alliance shares have underperformed the broader Standard & Poor's 500 index and lagged US healthcare peers, including CVS Health and UnitedHealth, as investors continue to reprice the stock’s risk profile after the guidance shock. Sector watchers note that the company’s valuation discount versus other US pharmacy and managed-care stocks has widened further.
At the same time, analysts highlight that challenges in the US drugstore channel are not unique to Walgreens Boots Alliance, pointing to soft front-of-store sales and margin pressure from generics and pharmacy benefit managers across the industry, according to a recent Financial Times sector analysis. The key debate now centers on how quickly the group can stabilize earnings and whether additional restructuring will be necessary.
How the company makes money
Walgreens Boots Alliance generates most of its revenue from retail pharmacy operations in the United States, where its stores dispense prescription medicines, sell over-the-counter drugs and offer health and wellness products. Internationally, the company operates Boots pharmacies and beauty outlets, while also running a wholesale pharmaceutical distribution business in selected markets.
Where the stock trades today
Walgreens Boots Alliance shares (US9314271019) trade on Nasdaq at $12.34 as of 06/19/2026, 14:30 CET.
Key facts on Walgreens Boots Alliance stock
- Company: Walgreens Boots Alliance, Inc.
- ISIN: US9314271019
- WKN: A12HJF
- Ticker: WBA
- Venue: Nasdaq
- Price (as of 06/19/2026, 14:30 CET): 12.34 USD
- Market cap: 10.2 billion USD (as of 06/19/2026)
- Sector / Industry: Health Care / Drug Retail
- Index membership: S&P 500
- Next earnings date: 07/11/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
